Michelle Hastings
Michelle Hastings is the Pfizer Upjohn Professor of Pharmacology at the University of
Michigan Medical School, Professor of Medicinal Chemistry in the College of
Pharmacy and Director of the RNA Therapeutics Core in the Center for RNA
Biomedicine. Her research is aimed at understanding the genetic and molecular
basis of disease and developing therapeutics that correct faulty gene expression by
targeting the RNA transcript using small molecule effectors and antisense
oligonucleotides (ASOs). Work in her lab has resulted in the discovery of new
treatment approaches for diseases such as cystic fibrosis, Usher syndrome,
Alzheimer’s, Parkinson’s, and Batten disease. Most recently, she designed, tested
and was involved in the development of an ASO medicine that is being used to treat
an ultra-rare form of CLN3 Batten disease, and is developing a similar type of ASO
to treat the more common cause of the disease.
Abstracts this author is presenting:
